Suppr超能文献

在悬浮培养的植物细胞中生产重组蛋白。

Production of recombinant proteins in suspension-cultured plant cells.

作者信息

Plasson Carole, Michel Rémy, Lienard David, Saint-Jore-Dupas Claude, Sourrouille Christophe, de March Ghislaine Grenier, Gomord Véronique

机构信息

Faculté des Sciences, Université de Rouen, Mont Saint Aignan, France.

出版信息

Methods Mol Biol. 2009;483:145-61. doi: 10.1007/978-1-59745-407-0_9.

Abstract

Plants have emerged in the past decade as a suitable alternative to the current production systems for recombinant pharmaceutical proteins and, today their potential for low-cost production of high quality, much safer and biologically active mammalian proteins is largely documented. Among various plant expression systems being explored, genetically modified suspension-cultured plant cells offer a promising system for production of biopharmaceuticals. Indeed, when compared to other plant-based production platforms that have been explored, suspension-cultured plant cells have the advantage of being totally devoid of problems associated with the vagaries of weather, pest, soil and gene flow in the environment. Because of short growth cycles, the timescale needed for the production of recombinant proteins in plant cell culture can be counted in days or weeks after transformation compared to months needed for the production in transgenic plants. Moreover, recovery and purification of recombinant proteins from plant biomass is an expensive and technically challenging business that may amount to 80-94% of the final product cost. One additional advantage of plant cell culture is that the recombinant protein fused with a signal sequence can be expressed and secreted into the culture medium, and therefore recovered and purified in the absence of large quantities of contaminating proteins. Consequently, the downstream processing of proteins extracted from plant cell culture medium is less expensive, which may/does balance the higher costs of fermentation. When needed for clinical use, recombinant proteins are easily produced in suspension-cultured plant cells under certified, controllable and sterile conditions that offer improved safety and provide advantages for good manufacturing practices and regulatory compliance. In this chapter, we present basic protocols for rapid generation of transgenic suspension-cultured cells of Nicotiana tabacum, Oriza sativa and Arabidopis thaliana. These systems are powerful tools for plant-made pharmaceuticals production in highly controlled conditions.

摘要

在过去十年中,植物已成为当前重组药物蛋白生产系统的合适替代品,如今,其低成本生产高质量、更安全且具有生物活性的哺乳动物蛋白的潜力已得到大量记录。在正在探索的各种植物表达系统中,基因改造的悬浮培养植物细胞为生物制药生产提供了一个有前景的系统。事实上,与已探索的其他基于植物的生产平台相比,悬浮培养植物细胞的优势在于完全不存在与天气多变、害虫、土壤及环境中基因流动相关的问题。由于生长周期短,与转基因植物生产所需的数月相比,在植物细胞培养中生产重组蛋白所需的时间尺度可以以转化后的天数或周数来计算。此外,从植物生物质中回收和纯化重组蛋白是一项昂贵且技术上具有挑战性的工作,其成本可能占最终产品成本的80 - 94%。植物细胞培养的另一个优势是,与信号序列融合的重组蛋白可以表达并分泌到培养基中,因此可以在不存在大量污染蛋白的情况下进行回收和纯化。因此,从植物细胞培养基中提取的蛋白质的下游加工成本较低,这可能/确实平衡了较高的发酵成本。当临床需要时,重组蛋白可以在经过认证、可控且无菌的条件下在悬浮培养的植物细胞中轻松生产,这些条件提高了安全性,并为良好生产规范和法规合规提供了优势。在本章中,我们介绍了快速生成烟草、水稻和拟南芥转基因悬浮培养细胞的基本方案。这些系统是在高度可控条件下生产植物源药物的强大工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验